A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Clinical trial NCT06736262 · TERMINATED

Trial details

NCT number: NCT06736262
Sponsor: Jasper Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Urticaria Chronic

Start date: 2024-11-26
Primary completion: 2026-07-21
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.